Management of Patients with Hepatitis B Immunity and Non-Reactive RPR

Interpretation of Hepatitis B Serology

The Centers for Disease Control and Prevention (CDC) considers anti-HBs ≥10 mIU/mL as the standard threshold for protective immunity against HBV infection, indicating strong immunity against hepatitis B virus infection in patients with HBsAb levels above this threshold 1, 2
Immunocompetent persons with anti-HBs ≥10 mIU/mL have long-term protection and do not need further periodic testing to assess anti-HBs levels, as demonstrated by guidelines from the CDC and other reputable sources 1, 3

A non-reactive RPR test indicates no evidence of syphilis infection, according to recommendations from the MMWR Recommendations and Reports 2
No further testing or treatment for syphilis is needed at this time for patients with a non-reactive RPR test, as stated in guidelines from the MMWR Recommendations and Reports 2

No additional hepatitis B vaccination is required for patients who have demonstrated strong immunity, as recommended by the MMWR Recommendations and Reports and the CDC 1, 3
No further serologic testing for hepatitis B is needed in immunocompetent individuals with anti-HBs ≥10 mIU/mL, according to guidelines from the MMWR Recommendations and Reports 4
Patients with protective immunity against hepatitis B virus should be informed that they are protected against future HBV infection, as stated in guidelines from the American Journal of Transplantation and the CDC 5

If a patient is immunocompromised, annual testing of anti-HBs may be warranted, as recommended by the Clinical Gastroenterology and Hepatology and the CDC 6, 1
For hemodialysis patients, a booster dose would be recommended if anti-HBs levels fall below 10 mIU/mL, according to guidelines from the American Journal of Transplantation and the CDC 5
For transplant candidates or recipients, regular monitoring of anti-HBs levels (once per year) is recommended with a booster dose if antibody levels fall under 10 mIU/mL, as stated in guidelines from the American Journal of Transplantation and the CDC 7, 5

No evidence suggests that patients with isolated anti-HBs positivity (without HBsAg or anti-HBc) need any further evaluation or monitoring if they are immunocompetent, according to guidelines from the MMWR Recommendations and Reports and the CDC 1, 3

The medical record should document that the patient has protective immunity against hepatitis B virus and a negative RPR test, as recommended by the CDC and the Praxis Medical Insights: Practical Summaries of Clinical Guidelines 1